Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Allakos Inc.
  6. Company
    ALLK   US01671P1003

ALLAKOS INC.

(ALLK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Allakos Inc.
Allakos Inc. is a clinical stage biopharmaceutical company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory and proliferative diseases. Its initial clinical focus is eosinophilic gastritis and/or eosinophilic duodenitis, inflammatory diseases of the gastrointestinal tract. The Company is focused on the development of lirentelimab (AK002) for the treatment of eosinophil and mast cell related diseases. The Company conducting clinical trials for other mast cell and eosinophil driven diseases including chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Its lead compound, AK002, is in clinical development, and its other product candidates are in preclinical development. The Company’s operations are located in Redwood City, California.

Number of employees : 125 people.
Managers
Name Title Age Since
Robert Alexander Chief Executive Officer & Director 50 2019
Adam Tomasi President & Chief Operating Officer 50 2021
Harlan Radford Chief Financial Officer - 2021
Ruby Casareno Vice President-Technical Operations - -
Craig Paterson Chief Medical Officer - 2021
John P. McKearn, Dr. Independent Director 66 2012
Steven P. James Independent Director 61 2016
Dan Janney Chairman 54 2017
Paul E. Walker Independent Director 45 2017
Robert E. Andreatta Independent Director 58 2018
Members of the board
Name Title Age Since
Dan Janney Chairman 54 2017
John P. McKearn, Dr. Independent Director 66 2012
Steven P. James Independent Director 61 2016
Robert Alexander Chief Executive Officer & Director 50 2019
Paul E. Walker Independent Director 45 2017
Robert E. Andreatta Independent Director 58 2018
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 54,313,379 50,825,822 93.6% 0 0.0% 93.6%
Shareholders
NameEquities%
Alta Partners Management Corp. 8,519,200 15.8%
Capital Research & Management Co. (World Investors) 6,614,358 12.2%
Capital Research & Management Co. (Global Investors) 4,912,458 9.10%
RiverVest Venture Management LLC 4,887,932 9.05%
Wellington Management Co. LLP 3,818,044 7.07%
The Vanguard Group, Inc. 3,370,178 6.24%
Bayer Aktiengesellschaft 2,779,157 5.15%
Fidelity Management & Research Co. LLC 2,313,467 4.28%
NEA Management Co. LLC 2,164,704 4.01%
Redmile Group LLC 2,131,796 3.95%
Company contact information
Allakos, Inc.
975 Island Drive
Suite 201
Redwood City, CA 94065

Phone : +1.650.597.5002
Web : http://www.allakos.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Allakos Inc.
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
ALLAKOS INC.-42.79%4 350
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678
BEIGENE, LTD.34.56%32 622
GENMAB A/S4.91%25 828
ARGENX SE1.82%14 364
ACCELERON PHARMA INC.39.71%10 932
NEUROCRINE BIOSCIENCES, INC.-9.25%8 252
HUALAN BIOLOGICAL ENGINEERING INC.-31.75%8 229
ASCENDIS PHARMA A/S-13.77%8 158
MIRATI THERAPEUTICS, INC.-37.73%7 551
ARROWHEAD PHARMACEUTICALS, INC.-6.14%7 528
LEGEND BIOTECH CORPORATION92.26%7 201
SAREPTA THERAPEUTICS, INC.-53.30%6 933
GW PHARMACEUTICALS PLC89.72%6 907
REMEGEN CO., LTD.10.63%6 601
BIOCON LIMITED-22.05%5 750
DENALI THERAPEUTICS INC.-46.25%5 498